Download PDF
Viszeralchirurgie 2005; 40(4): 250-254
DOI: 10.1055/s-2005-836647
Originalarbeit

© Georg Thieme Verlag Stuttgart · New York

Möglichkeiten der Response-Prädiktion neoadjuvanter und adjuvanter Therapien beim Ösophagus- und Magenkarzinom

Potential Response Prediction in the Neoadjuvant and Adjuvant Therapy of Esophageal and Gastric CancerD. Vallböhmer1 , H. J. Lenz1
  • 1University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA
Further Information

Publication History

Publication Date:
13 September 2005 (online)

    Permissions and Reprints

Zusammenfassung

Das Ösophagus- und Magenkarzinom stellen weltweit zwei der Haupttodesursachen durch maligne Erkrankungen dar. Dazu ist das Adenokarzinom der Speiseröhre aktuell die schnellst ansteigende bösartige Grunderkrankung in den westlichen Ländern. Da diese Tumorformen zumeist in einem fortgeschrittenen Stadium diagnostiziert werden, ist häufig ein multimodales Therapieprozedere erforderlich. Trotz großer Fortschritte sowohl der Operationstechniken als auch neoadjuvanter/adjuvanter Behandlungsstrategien, profitieren nur ca. 20 % der Patienten mit einem fortgeschrittenen Ösophaguskarzinom von einer neoadjuvanten Therapie. Aus diesem Grund ist es notwendig prädiktive/prognostische Faktoren zu etablieren, die ein individuelles Behandlungskonzept ermöglichen. Mittels innovativer, molekularbiologischer Techniken ist es jedoch in den letzten Jahren gelungen, Marker zu beschreiben, die eine Response-Prädiktion neoadjuvanter und adjuvanter Therapien beim Ösophagus- und Magenkarzinom zulassen. Dabei wurden verschiedenartige Faktoren beschrieben, wie z. B. angiogenetische Faktoren, Enzyme involviert in DNS-Reparaturmechansimen, Faktoren des 5-Fluorouracil-Metabolismus, Tumorsuppressorgene oder Wachstumsfaktor-Rezeptoren. Die zumeist retrospektiv erzielten Studienergebnisse sind Erfolg versprechend, müssen aber in prospektiven Studien validiert werden.

Abstract

Esophageal and gastric carcinomas constitute a major cause of cancer deaths worldwide and esophageal adenocarcinoma is currently the most rapidly increasing cancer in the Western world. These tumors are usually detected at an advanced stage, requiring a multimodal concept. Despite improvements in surgical techniques as well as neoadjuvant/adjuvant therapies, for example less than 20 % of the patients with advanced esophageal cancer benefit from neoadjuvant therapy. Therefore predictive/prognostic markers are necessary to achieve an individual management concerning (radio-) chemotherapy and increase efficacy. Recently molecular markers have been identified using innovative, molecularbiological technologies to predict response to neoadjuvant and adjuvant therapies in esophageal and gastric cancer. These factors are enzymes of angiogenesis, enzymes involved in the DNA-repair-system, factors of the 5-fluorouracil metabolism, tumorsupressor genes or growth-factor receptors. These markers found mainly in retrospective studies are prom-ising but prospective studies are needed to validate these mark-ers.

Schlüsselwörter

Ösophagus-/Magenkarzinom - Response-Prädiktion - molekulare Faktoren

Key words

Esophageal/gastric cancer - response prediction - molecular factors

Literatur

  • 1 Wei J T, Shaheen N. The changing epidemiology of esophageal adenocarcinoma.  Semin Gastrointest Dis. 2003;  14 112-127
    PubMedGoogle Scholar
  • 2 Crew K D, Neugut A I. Epidemiology of upper gastrointestinal maligSnancies.  Semin Oncol. 2004;  31 450-464
    CrossrefPubMedGoogle Scholar
  • 3 Muhr-Wilkenshoff F, Stahl M, Faiss S, Zeitz M, Scherubl H. Current diagnosis and therapy of esophageal carcinoma.  Z Gastroenterol. 2004;  42 615-621
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Pohl H, Welch H G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.  Natl Cancer Inst. 2005;  97 142-146
    CrossrefPubMedGoogle Scholar
  • 5 Greer S E, Goodney P P, Sutton J E, Birkmeyer J D. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis.  Surgery. 2005;  137 172-177
    CrossrefPubMedGoogle Scholar
  • 6 Zacherl J, Sendler A, Stein H J. et al . Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus.  World J Surg. 2003;  27 1067-1074
    PubMedGoogle Scholar
  • 7 Brucher B L, Stein H J, Zimmermann F. et al . Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial.  Eur J Surg Oncol. 2004;  30 963-971
    CrossrefPubMedGoogle Scholar
  • 8 Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy.  Oncogene. 2000;  19 6550-6565
    CrossrefPubMedGoogle Scholar
  • 9 Miyazono F, Metzger R, Warnecke-Eberz U. et al . Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.  Br J Cancer. 2004;  91 666-672
    PubMedGoogle Scholar
  • 10 Schneider S, Uchida K, Brabender J. et al . Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.  Am Coll Surg. 2005;  200 336-344
    PubMedGoogle Scholar
  • 11 Warnecke-Eberz U, Metzger R, Miyazono F. et al . High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.  Clin Cancer Res. 2004;  10 3794-3799
    PubMedGoogle Scholar
  • 12 Rosell R, Taron M, Ariza A. et al . Molecular predictors of response to chemotherapy in lung cancer.  Semin Oncol. 2004;  31 (Suppl 1) 20-27
    PubMedGoogle Scholar
  • 13 Kulke M H, Odze R D, Mueller J D, Wang H, Redston M, Bertagnolli M M. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.  J Thorac Cardiovasc Surg. 2004;  127 1579-1586
    CrossrefPubMedGoogle Scholar
  • 14 Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann E H, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer.  Eur J Cardiothorac Surg. 2002;  21 657-663
    PubMedGoogle Scholar
  • 15 Shimada H, Hoshino T, Okazumi S. et al . Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma.  Br J Cancer. 2002;  86 552-557
    CrossrefPubMedGoogle Scholar
  • 16 Lowe S W, Bodis S, McClatchey A. et al . p53 status and the efficacy of cancer therapy in vivo.  Science. 1994;  266 807-810
    CrossrefPubMedGoogle Scholar
  • 17 Shimada Y, Watanabe G, Yamasaki S. et al . Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity.  Eur J Cancer. 2000;  36 987-993
    CrossrefPubMedGoogle Scholar
  • 18 Nakashima S, Natsugoe S, Matsumoto M. et al . Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma.  Anticancer Res. 2000;  20 1933-1937
    PubMedGoogle Scholar
  • 19 Kitamura K, Saeki H, Kawaguchi H. et al . Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer.  Hepatogastroenterology. 2000;  47 419-423
    PubMedGoogle Scholar
  • 20 Kuwahara M, Hirai T, Yoshida K. et al . p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer.  Dis Esophagus. 1999;  12 116-119
    CrossrefPubMedGoogle Scholar
  • 21 Ikeguchi M, Maeta M, Kaibara N. Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer.  Int J Mol Med. 2001;  7 413-417
    PubMedGoogle Scholar
  • 22 Roder D M. The epidemiology of gastric cancer.  Gastric Cancer. 2002;  5 (Suppl 1) 5-11
    CrossrefPubMedGoogle Scholar
  • 23 Hundahl S A, Phillips J L, Menck H R. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis.  Cancer. 2000;  88 921-932
    CrossrefPubMedGoogle Scholar
  • 24 Berger S H, Jenh C H, Johnson L F, Berger F G. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.  Mol Pharmacol. 1985;  28 461-467
    PubMedGoogle Scholar
  • 25 Lenz H J, Leichman C G, Danenberg K D. et al . Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.  J Clin Oncol. 1996;  14 176-182
    PubMedGoogle Scholar
  • 26 Heggie G D, Sommadossi J P, Cross D S, Huster W J, Diasio R B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.  Cancer Res. 1987;  47 2203-2206
    PubMedGoogle Scholar
  • 27 Takabayashi A, Iwata S, Kawai Y. et al . Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy.  Int J Oncol. 2000;  17 889-895
    PubMedGoogle Scholar
  • 28 Metzger R, Leichman C G, Danenberg K D. et al . ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.  J Clin Oncol. 1998;  16 309-316
    PubMedGoogle Scholar
  • 29 Terashima M, Fujiwara H, Takagane A. et al . Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.  Gastric Cancer. 2003;  6 (Suppl 1) 71-81
    PubMedGoogle Scholar
  • 30 Suda Y, Kuwashima Y, Tanaka Y, Uchida K, Akazawa S. Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines.  Anticancer Res. 1999;  19 805-810
    PubMedGoogle Scholar
  • 31 Grau J J, Domingo-Domenech J, Morente V. et al . Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur.  Oncology. 2004;  66 226-233
    CrossrefPubMedGoogle Scholar
  • 32 Fondevila C, Metges J P, Fuster J. et al . p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.  Br J Cancer. 2004;  90 206-215
    CrossrefPubMedGoogle Scholar
  • 33 Diez M, Medrano M J, Gutierrez A. et al . P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.  Anticancer Res. 2000;  20 3929-3933
    PubMedGoogle Scholar
  • 34 Hurwitz H, Fehrenbacher L, Novotny W. et al . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  SN Engl J Med. 2004;  350 2335-2342
    CrossrefPubMedGoogle Scholar
  • 35 Cunningham D, Humblet Y, Siena S. et al . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Engl J Med. 2004;  351 337-345
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. H. J. Lenz

University of Southern California · Norris Comprehensive Cancer Center

1441 Eastlake Ave.

Suite 3456

Los Angeles

CA 90033

Email: lenz@usc.edu

      >